Glycogen Storage Disease
Conditions
Brief summary
To compare efficacy of Glycosade® with uncooked corn starch (UCCS for the dietary management of hepatic glycogen storage diseases (GSD).
Detailed description
'Glyde' is a prospective, randomised, double-blind, crossover trial to compare the effects of two different starches used in the dietary management of GSD. The study will recruit 64 patients from six centres in the UK, USA, France and The Netherlands. The planned duration per participant is 2 years. Participants will be randomised into two equally sized groups: Arm A- Glycosade intake given first, followed by UCCS 1-6 weeks later Arm B- UCCS intake given first, followed by Glycosade 1-6 weeks later. The objective of this trial is to establish whether Glycosade® improves outcomes for patients with GSD compared to UCCS therapy by comparing the duration of normal blood sugars, lactate and ketone levels of patients with hepatic GSD (Types I, III, VI and IX) post equivalent intakes of UCCS and Glycosade®. The first part consists of two (blinded) 12 hour starch load tests administered randomly within a maximum 6 week period. Participants will be randomised to receive either UCCS or Glycosade® for the initial intervention period crossing over to the other product for the second intervention period (part 1). The second part (unblinded) is a 24 month open follow up whereby participant's will continue on the product considered most suitable by the clinician and patient.
Interventions
DIETARY_SUPPLEMENTMedical Food - Glycosade
double blind randomised crossover of 2 starches - glycosade and UCCS
Sponsors
University College London Hospitals
University of Florida
Great Ormond Street Hospital for Children NHS Foundation Trust
University Medical Center Groningen
Hôpital Necker-Enfants Malades
Vitaflo International, Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
2 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed by either genetic mutation analysis or enzymology study (this includes patients with only a single mutation but who also have supportive enzymology consistent with the condition). For those whom mutation analysis is not completed this will be assessed during the study. * Aged 2 years or older (5 years or older in the USA) * Established on full intake of uncooked corn starch therapy for at least 6 months
Exclusion criteria
* Women who are pregnant or breastfeeding at the start of the study or planning to become pregnant during the study will be excluded. * children less than 2 years of age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess if Glycosade® will result in improved blood glucose, lactate and ketone levels in a larger group of patients with GSD I, III, VI & IX as measured by duration of normal blood glucose levels or prevention of ketosis | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| 1. The insulin area under the curve during dietary management with UCCS compared to dietary management with Glycosade®. | 24 hours |
| 2. The area under the curve in lactate, BOHB, during dietary management with UCCS compared to dietary management with Glycosade®. | 24 hours |
Countries
France, Netherlands, United Kingdom, United States
Outcome results
None listed